Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Although the underlying pathophysiology that causes ADHD remains unclear, evidence suggests that dysregulation in noradrenergic and dopaminergic pathways plays a critical role in suboptimal executive functioning within prefrontal regions of the brain, which are involved in attention and memory. It is grouped under the following drug class(es): Psychotropic agents. Its therapeutic use is listed as ADHD agents and central nervous system (CNS) agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Tomoxetina and Strattera. Its PubChem CID is 54841.
Atomoxetine
| CAS No | 83015-26-3 |
|---|---|
| Molecular Formula | C17H21NO |
| Molecular Weight | 255.35 g/mol |
| Synonyms | (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD).
The listed CAS number is 83015-26-3.
The listed molecular formula is C17H21NO.
The listed molecular weight is 255.35 g/mol.
(3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine.
The source lists Tomoxetina and Strattera.